Safety and efficacy of rivastigmine in adolescents with down syndrome: Long-term follow-up

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 6, 2010, Pages 517-520

  Heller, James H ^a   Spiridigliozzi, Gail A ^a   Crissman, Blythe G ^a   McKillop, Jane Anne ^a   Yamamoto, Haru ^b   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

ADAPTIVE BEHAVIOR; ADOLESCENT; CLINICAL ARTICLE; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LANGUAGE; LANGUAGE ABILITY; LONG TERM CARE; MALE;

ADOLESCENT; COGNITION; DOWN SYNDROME; FOLLOW-UP STUDIES; HUMANS; LANGUAGE DISORDERS; LANGUAGE TESTS; MALE; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; TIME FACTORS;

EID: 78650646336     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0099     Document Type: Conference Paper

References (13)

1. Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R: Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics 16:771-774, 2006.
2. Canfield MA, Honein MA, Yuskiv N, et al.: National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 76:747- 756, 2006.
3. Cummings JL: Chiolinesterase inhibitors: Expanding applications. Lancet 356:1-4, 2000.
4. Harrison J, Maruff P: Measuring the mind: Assessing cognitive change in clinical drug trials. Expert Rev Clin Pharmacol 1:471- 473, 2008.
5. Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan JA, Eells RL, Li JS, Doraiswamy PM, Krishnan KR, Kishnani PS: Safety and efficacy of rivastigmine in adolescents with Down syndrome: A preliminary 20-week, open-label study. JCAP 16:755-765, 2006.
6. Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS: Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial. Am J Med Genet 130A:325-326, 2004.
7. Heller JH, Spiridigliozzi GA, Kishnani PS: TOVER: Test of Verbal Expression and Reasoning. Durham, NC: Duke University Medical Center; 2000.
8. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D: Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard 108:367-372, 2003.
9. Kishnani PS, Sommer B, Handen B, et al.: The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet 149:1641-1654, 2009.
10. Korkman M, Kirk U, Kemp S: NEPSY: A Developmental Neuropsychological Assessment, Manual. San Antonio, TX: The Psychological Corporation; 1998.
11. Roid GH, Miller LJ: Leiter International Performance Scale-Revised. Wood Dale, IL: Stoelting; 1997.
12. Sparrow SS, Balla DA, Cicchetti DV: Vineland Adaptive Behavior Scales-Interview Edition (Survey Form). Circle Pines: American Guidance Service; 1984.
13. Wiig E, Secord W, Semel E: Clinical Evaluation of Language Fundamentals-Preschool. San Antonio, TX: The Psychological Corporation; 1992.